You are here

Pharming

Novartis buys priority review voucher from Pharming for discount price of $21M

Fierce Biotech

Thu, 06/1/23 - 11:40 am

priority review vouchers

FDA approves Pharming drug for ultra-rare immunodeficiency disease

Endpoints

Sun, 03/26/23 - 11:16 pm

Former Novartis drug for ultra-rare disease gets speedy FDA review

Endpoints

Wed, 09/28/22 - 10:58 am

Corporate and regulatory developments over the Christmas period

EP Vantage

Thu, 01/2/20 - 11:39 pm

Ono Pharmaceutical

Xyphos Biosciences

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

Pharmaforum

Thu, 10/17/19 - 10:30 am

Novartis sells phase 3 rare disease drug to Pharming

Fierce Biotech

Tue, 08/13/19 - 10:06 am